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The identification of raft-derived tau-associated vesicles that are incorporated into immature
tangles and paired helical filaments
Aims: Neurofibrillary tangles (NFTs), a cardinal
pathological feature of neurodegenerative disorders,
such as Alzheimer’s disease (AD) are primarily com-
posed of hyper-phosphorylated tau protein. Recently,
several other molecules, including flotillin-1, phos-
phatidylinositol-4,5-bisphosphate [PtdIns(4,5)P2] and
cyclin-dependent kinase 5 (CDK5), have also been
revealed as constituents of NFTs. Flotillin-1 and
PtdIns(4,5)P2 are considered markers of raft microdo-
mains, whereas CDK5 is a tau kinase. Therefore, we
hypothesized that NFTs have a relationship with raft
domains and the tau phosphorylation that occurs
within NFTs. Methods: We investigated six cases of
AD, six cases of other neurodegenerative diseases
with NFTs and three control cases. We analysed the
PtdIns(4,5)P2-immunopositive material in detail,
using super-resolution microscopy and electron micro-
scopy to elucidate its pattern of expression. We also
investigated the spatial relationship between the
PtdIns(4,5)P2-immunopositive material and tau
kinases through double immunofluorescence analysis.
Results: Pretangles contained either paired helical fila-
ments (PHFs) or PtdIns(4,5)P2-immunopositive small
vesicles (approximately 1 lm in diameter) with nearly
identical topology to granulovacuolar degeneration
(GVD) bodies. Various combinations of these vesicles
and GVD bodies, the latter of which are pathological
hallmarks observed within the neurons of AD
patients, were found concurrently in neurons. These
vesicles and GVD bodies were both immunopositive
not only for PtdIns(4,5)P2, but also for several tau
kinases such as glycogen synthase kinase-3b and
spleen tyrosine kinase. Conclusions: These observa-
tions suggest that clusters of raft-derived vesicles that
resemble GVD bodies are substructures of pretangles
other than PHFs. These tau kinase-bearing vesicles
are likely involved in the modification of tau protein
and in NFT formation.
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Introduction
Alzheimer’s disease (AD) is pathologically characterized
by the pathological presence of extracellular neuritic pla-
ques, polymorphous amyloid beta protein deposits, and
intracellular neurofibrillary tangles (NFTs) composed of
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hyper-phosphorylated tau. Granulovacuolar degenera-
tion (GVD) bodies are also pathological hallmarks in the
neurons of AD patients [1]. We previously reported that
charged multivesicular body protein 2B (CHMP2B), an
endosome-related protein, and cyclin-dependent kinase
5 (CDK5), a tau kinase, are present in GVD bodies [2,3].
We have also revealed that phosphatidylinositol-4,5-
bisphosphate [PtdIns(4,5)P2], a phospholipid associated
with lipid rafts, exhibits identical immunoreactivity in
GVD bodies and NFTs [4]. In addition, double
immunofluorescence staining revealed that PtdIns(4,5)
P2-immunopositive granules within NFTs were not colo-
calized with phosphorylated tau. These results led us to
speculate that GVD bodies and NFTs share components
in terms of their origin but have different modes of
formation.
Paired helical filaments (PHFs) formed by hyper-
phosphorylated tau protein are the major components
of NFTs; however, several molecules in addition to the
tau protein, such as flotillin-1 [5], glycogen synthase
kinase (GSK)-3b [6], casein kinase 1 (CK-1) [7–9] and
CDK5 [10,11], have been detected in NFTs. The patho-
logical consequences of the presence of these molecules
have not yet been fully shown. In addition, through
electron microscopic observations, Okamoto et al. [12]
reported the accumulation of small vesicles and GVD
bodies adjacent to PHFs. These results suggest that
some uncharacterized materials other than PHFs might
be novel components of NFTs.
In the present study, we aimed to explore these
non-PHF materials in NFTs using super-resolution
microscopy and electron microscopy and to address the
potential pathological consequences of their presence.
Materials and methods
Subjects
Six cases of AD [mean age = 76.5 years  8.4 stan-
dard deviations of the mean (SDM)] and six cases of
other neurodegenerative diseases with NFTs [mean
age = 69.0 years  11.2 SDM], including one case each
of myotonic dystrophy, pantothenate kinase-associated
neurodegeneration (PKAN), corticobasal degeneration,
Parkinson’s disease (PD), multiple system atrophy
(MSA) and amyotrophic lateral sclerosis, were selected.
Three control cases [67-year-old female, 70-year-old
female, 73-year-old female] free of tau pathology (Ab
phase = 0, NFT stage = 0) were also examined. The
clinical profiles, GVD stages [13], Thal phases of amy-
loid beta protein deposition [14], Braak NFT stages
[15], frequency of neuritic plaques according to the
method of the Consortium to Establish a Registry for
Alzheimer’s Disease [16], and degrees of AD neu-
ropathologic change [17] of these patients are shown
in Table 1. The use of human materials conformed to
the ethical guidelines of Hiroshima University Graduate
School of Biomedical and Health Sciences, Hiroshima,
Japan. All AD cases fulfilled the quantitative neu-
ropathological criteria for the diagnosis of AD of the
National Institute on Aging-Alzheimer’s Association
guidelines for the neuropathologic assessment of AD;
Table 1. Subject characteristics
Case no. Diagnosis Gender Age GVD stage Ab phase NFT stage CERAD AD neuro-pathologic change
1 AD M 73 5 5 6 Frequent High
2 AD F 66 5 5 6 Frequent High
3 AD F 75 5 5 6 Frequent High
4 AD F 85 5 5 5 Frequent High
5 AD F 72 5 5 5 Frequent High
6 AD M 88 5 5 5 Frequent High
7 MyD M 57 4 3 2 Sparse Low
8 PKAN F 57 5 1 5 Sparse Low
9 CBD F 75 2 3 3 Frequent Intermediate
10 PD M 86 1 4 2 Frequent Low
11 MSA F 72 1 3 2 Frequent Low
12 ALS F 67 1 3 1 Sparse Low
AD, Alzheimer’s disease; MyD, myotonic dystrophy; PKAN, pantothenate kinase-associated neurodegeneration; CBD, corticobasal degener-
ation; PD, Parkinson’s disease; MSA, multiple system atrophy; ALS, amyotrophic lateral sclerosis; F, female; M, male; Age, age at death;
GVD, granulovacuolar degeneration; NFT, neurofibrillary tangle; CERAD, the Consortium to Establish a Registry for Alzheimer’s Disease.
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that is, an AD Neuropathologic Change score of A3, B3
or C3 [17].
Brain tissue
Autopsies were performed within 24 h of death. Brains
were fixed in 10% (v/v) formalin for 3 weeks, and
3-lm- or 5-lm-thick paraffin-embedded sections were
prepared for subsequent procedures unless otherwise
indicated. Unless otherwise indicated, we observed the
subiculum and cornu ammonis (CA) subfields 1–4.
Antibodies
The following antibodies were used for the immunohis-
tochemistry and immunofluorescence studies: mouse
monoclonal IgM-type anti-PtdIns(4,5)P2 (2C11, dilu-
tion 1:500 for immunohistochemistry, 1:100 for
immunofluorescence staining; Santa Cruz Biotech,
Santa Cruz, CA, USA); mouse monoclonal IgG-type
anti-phosphorylated tau [(AT8, dilution 1:800; Inno-
genetics, Ghent, Belgium), (AT100, dilution 1:100;
Thermo Scientific Pierce, Carlsbad, CA, USA), (AT270,
dilution 1:200; Thermo Scientific Pierce; mouse mono-
clonal)], IgG-type anti-Asp421 truncated tau (Tau-C3,
dilution 1:200; Invitrogen, Frederick, MN, USA), anti-
tau (3-repeat isoform RD3) (8E6/C11, dilution 1:300;
Merck Millipore, Darmstadt, Germany) and anti-tau (4-
repeat isoform RD4) (1E1/A6, dilution 1:100; Merck
Millipore); and rabbit polyclonal anti-CHMP2B
(ab33174, dilution 1:600; Abcam, Cambridge, UK),
anti-phosphatidylinositol-binding clathrin assembly
protein (PICALM) (HPA019053, dilution 1:200;
Sigma-Aldrich, St. Louis, MO, USA), anti-phosphory-
lated mitogen-activated protein kinase kinase (pMEK)
1/2 (Ser217/221) (dilution 1:50; New England Bio-
Labs, Ipswich, MA, USA), anti-GSK-3b [pY216]/GSK-3a
[pY279] (44-604G, dilution 1:100; Life Technologies,
Carlsbad, CA, USA), anti-phosphorylated spleen tyro-
sine kinase (pSyk) (AP3271a, dilution 1:50; Abgent,
San Diego, CA, USA) and anti-CK-1d (ab85320,
dilution 1:50; Abcam).
Immunohistochemistry
The sections were deparaffinized and rehydrated.
For antigen retrieval, sections were microwaved in dis-
tilled water for 10 min, followed by washing in
phosphate-buffered saline (PBS) for 3 min. Deparaf-
finized sections were then incubated with 3% H2O2 in
PBS for 60 min to eliminate endogenous peroxidase
activity in the tissue. Each section was incubated over-
night at 4°C with the primary antibodies described
above. The sections were then washed three times in
PBS and incubated with horseradish peroxidase (HRP)-
conjugated anti-mouse or anti-rabbit antibodies for
30 min at room temperature. The avidin–biotin com-
plex method was used to detect the mouse monoclonal
IgM-type anti-PtdIns(4,5)P2 (clone 2C11) antibody.
The sections were then washed three times in PBS and
incubated at room temperature with 3, 3-diaminobenzi-
dine (Dako, Glostrup, Denmark).
Quantitative analysis
Quantitative analysis of PtdIns(4,5)P2-positive neurons
was performed for different regions of the hippocampus,
including CA1, CA2–4 and the subiculum. The num-
bers of neurons-containing PtdIns(4,5)P2-positive
structures were counted sequentially over the entire
area, using light microscopy at 4009 magnification.
We counted the neurons-containing GVD bodies, NFTs
and combined structures separately and evaluated the
numbers in different regions.
Immunofluorescence staining
We also performed double staining on sections,
including sections from the hippocampus and parahip-
pocampal gyrus, for further characterization. First,
paraffin-embedded sections were irradiated with UV
light overnight at 4°C to reduce autofluorescence by
photobleaching the tissue sections. After irradiation, we
applied the same primary antibodies described above.
The mouse monoclonal IgM-type anti-PtdIns(4,5)P2
(clone 2C11) antibody was detected using a Fluorescein
Avidin DCS kit (A-1100; Vector Laboratories,
Burlingame, CA, USA). The other primary antibodies
were detected using the tyramide signal amplification
(TSA) method with HRP-conjugated secondary antibod-
ies and the TSATM KIT#4, which contains Alexa FluorTM
568 tyramide (InvitrogenTM, Eugene, OR, USA). In cases
using both anti-mouse IgM and anti-mouse IgG anti-
bodies as secondary antibodies, a goat polyclonal HRP-
conjugated anti-mouse IgG Fc fragment antibody
(ab97265, dilution 1:1000; Abcam) was used to detect
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the mouse monoclonal IgG-type primary antibody to
prevent cross-reactions between the anti-mouse IgM
and IgG antibodies. The slides were mounted with
Vectashield (Vector Laboratories) and observed under
an LSM 510 confocal laser-scanning microscope (Carl
Zeiss AG, Oberkochen, Germany). After obtaining
images showing double staining for PtdIns(4,5)P2 and
CHMP2B, PtdIns(4,5)P2 and AT8, PtdIns(4,5)P2 and
RD3, or PtdIns(4,5)P2 and RD4, the same sections
were subjected to Gallyas staining, and the same
microscope field was identified [18].
To quantify the degree of colocalization of PtdIns
(4,5)P2 with AT8, we performed fluorescence intensity
line scanning using ZEN Software (Carl Zeiss AG), and
the Pearson product-moment correlation coefficients
were obtained, using Microsoft Excel 2007 according to
a previously reported method [19].
3D structured illumination microscopy (3D-SIM)
Furthermore, to observe the detailed spatial pattern of
PtdIns(4,5)P2 and AT8 by super-resolution imaging
with three-dimensional structured illumination micro-
scopy (3D-SIM), 3-lm-thick sections were subjected to
double immunofluorescence staining for PtdIns(4,5)P2
and AT8, using the following secondary antibodies:
Alexa FluorTM 488 goat anti-mouse IgM mu chain-
specific (ab150121, dilution 1:1000; Abcam) and Alexa
FluorTM 568 goat anti-mouse IgG (dilution 1:1000;
Molecular Probes, Eugene, OR, USA). The slides were
coverslipped with Vectashield 1000 and cover glass
(170 lm in thickness, grade no. 1S) and were observed
under a DeltaVision OMX V4 system (GE Healthcare,
Washington, DC, USA) equipped with 405, 488, 568,
and 642 nm solid lasers, sCMOS cameras (PCO Edge,
2K 9 2K, PCO), and a 609/1.42 NA plan Apochromat
oil-immersion objective (Olympus, Tokyo, Japan). The
super-resolution images were obtained as previously
described [20]. Briefly, optical transfer functions were
created for each colour channel from recordings of 0.1-
lm-diameter fluorescent beads. 3D-SIM image stacks
were reconstructed, using the softWoRx software pack-
age, version 6.1.1 (GE Healthcare) with the following
settings: pixel size 80 nm; channel-specific optical trans-
fer functions; Wiener filter 0.001; keeping negative
intensities; default background intensity value of 65;
drift correction with respect to the first angle; and
custom K0 guess angles for camera positions.
Electron microscopy
The subiculum of the hippocampus was fixed in 9%
formaldehyde, cut into small pieces, postfixed in 1%
osmium tetroxide for 2 h, dehydrated and embedded in
epoxy resin. Specimens were subjected to electron micro-
scopic analysis. Full-thickness blocks were cut, rapidly
placed in cold buffered glutaraldehyde and fixed for 18–
20 h at 4°C. The strips were rinsed in PBS and further
fixed in osmium tetroxide for 1 h at room temperature;
then, they were dehydrated in ethanol and embedded in
Epon. One-micrometer sections that were stained with
toluidine blue were used for the correlation analysis and
for the selection of areas for EM study. Thin sections
were cut with a diamond knife, stained with uranyl acet-
ate and lead citrate, and examined under a JEM-1230
(JOEL, Tokyo, Japan) transmission electron microscope.
Results
Various patterns of PtdIns(4,5)P2
immunoreactivity are found in pyramidal
neurons of individuals with AD and other
neurodegenerative diseases
Some PtdIns(4,5)P2-immunopositive materials exhib-
ited 3- to 5-lm-diameter vesicular structures with
Figure 1. Double immunofluorescence staining for phosphatidylinositol-4,5-bisphosphate [PtdIns(4,5)P2] (green) and casein kinase 1d
(CK-1d) (red) (A). CK-1d, a marker of granulovacuolar degeneration (GVD) bodies, localized with PtdIns(4,5)P2, suggesting that PtdIns
(4,5)P2 is a constituent of GVD bodies. Immunohistochemistry for PtdIns(4,5)P2 in neuronal cells in tissue from several Alzheimer’s
disease (AD) cases (B). Fine PtdIns(4,5)P2-immunopositive granules accumulated in the shape of neurofibrillary tangles. Some of the
PtdIns(4,5)P2-immunopositive structures resemble GVD bodies (arrows), and others resemble Neurofibrillary tangles (NFTs) (arrowheads).
The neuronal cells that contained PtdIns(4,5)P2-immunopositive structures were classified into three types: those with only GVD body,
those with only NFT, and those with both structures. The numbers of neurons containing only GVD body-like structures, only NFT-like
structures, and those with both structures in the subiculum, CA1 and CA2–4 of the hippocampus in each AD case (C). Schematic
representation of the distribution of PtdIns (4,5) P2-positive only GVD body-like structures, only NFT-like structures, and those with both
structures in the temporal lobe of an AD patient (case 4) (D). Each dot represents a cell containing GVD bodies (green), NFTs (red) or
both (blue). Scale bars: (A) 10 lm (B, a) 100 lm (B, b–e) 10 lm.
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central granules that were surrounded by a halo-like
clear zone and an outer membrane, characteristics that
are indicative of GVD bodies. CK-1d, a marker of GVD
bodies [9,13], was colocalized with PtdIns(4,5)P2, sug-
gesting that PtdIns(4,5)P2 is a constituent of GVD bod-
ies, as previously reported (Figure 1A) [4]. The other
PtdIns(4,5)P2-immunopositive materials exhibited
granules that were clustered and piled up like NFTs.
Some neurons contained both types of structures, and
others had only one or the other (Figure 1B).
The median numbers of neurons containing only
PtdIns(4,5)P2-positive GVD bodies in the subiculum,
CA1 and CA2–4 of the hippocampus were 15.5, 53.5
and 101 respectively, in the samples from the patients
with AD. Those containing PtdIns(4,5)P2-positive NFTs
only were 104 (subiculum), 322.5 (CA1), and 947.5
(CA2–4). A considerable number of neurons contained
both GVD bodies and NFTs (Figure 1C), but only a
small number (<15) of each PtdIns(4,5)P2-positive
structure was observed in all fields in the samples from
the non-tauopathy control. The distribution patterns of
each structure were similar throughout the temporal
lobe, although they were predominantly located in the
hippocampus (Figure 1D).
In the samples from individuals with other neurode-
generative diseases, neuronal cells containing smaller
PtdIns(4,5)P2-immunopositive granular structures that
were shaped like NFTs and/or larger GVD body-like
vesicular structures were also observed mainly in the
hippocampus; however, many fewer of these cells were
observed in the samples from patients with other neu-
rodegenerative diseases than in the AD tissue (Figure 2).
Figure 2. Immunohistochemistry for phosphatidylinositol-4,5-bisphosphate [PtdIns(4,5)P2] in neuronal cells in tissue samples from
patients with other neurodegenerative diseases. Neuronal cells containing PtdIns(4,5)P2-immunopositive structures similar to those in
the Alzheimer’s disease samples were observed in myotonic dystrophy (a), pantothenate kinase-associated neurodegeneration (b),
corticobasal degeneration (c), Parkinson’s disease (d), multiple system atrophy (e) and amyotrophic lateral sclerosis (f). Scale bars: 20 lm.
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Similar-staining patterns of PtdIns(4,5)P2-immunoposi-
tive materials were also observed in the other AD cases.
PtdIns(4,5)P2-immunopositive small granules
are present within pretangles and NFTs at a
relatively early stage
Double immunofluorescence staining for PtdIns(4,5)P2
and several proteins related to GVD bodies or NFTs
revealed the presence of PtdIns(4,5)P2-immunopositive
granules, which were smaller than GVD bodies and
were surrounded by phosphorylated tau (Figure 3).
These PtdIns(4,5)P2-immunopositive granules were
immunonegative for CHMP2B (Figure 3a). Furthermore,
the signal for these PtdIns(4,5)P2-immunopositive gran-
ules did not overlap with that for AT8 (Figure 3c).
From the viewpoint of tangles, the signal for the
PtdIns(4,5)P2-immunopositive granules clearly colocal-
ized with that for RD4 (Figure 3e) but only partially
colocalized with that for RD3 (Figure 3g). In addition,
some of these granules were present in the part of the
cytoplasm of the neuronal cells that was negative for
Gallyas-Braak staining (Figure 3b, d, f, h). Hara et al.
[21] reported that an intraneuronal profile shift from
RD3/4+ pretangles to RD3+/4 ghost tangles by way
of RD3+/4+ NFTs might be the basis of the regional
gradation that occurs during the progression of NFT
pathology. In our study, the PtdIns(4,5)P2-immunopo-
sitive granules were immunopositive for RD4 but not
for RD3, a characteristic that is similar to that of pre-
tangles. The Tau-C3 antibody specifically recognizes
the form of tau that is truncated at Asp421 [22]; this
truncation is an early molecular event in tau aggrega-
tion that occurs prior to PHF formation [23]. By con-
trast, mature NFTs exhibit positive AT100 (pT212 and
pS214) and AT270 (pT181) immunoreactivity [23,24].
PtdIns(4,5)P2 was not colocalized with AT100 or
AT270, but was colocalized with Tau-C3, which also
suggests that PtdIns(4,5)P2 is associated with an early
stage of NFT development (Figure 3i–l).
PtdIns(4,5)P2-immunopositive small granules
are colocalized with PICALM, pMEK and the
tau kinases GSK-3b and pSyk
Phosphatidylinositol-binding clathrin assembly protein
is colocalized with phosphorylated tau not only in NFTs
but also in GVD bodies [25]. In the present study,
double immunofluorescence staining for PtdIns(4,5)P2
and PICALM revealed that PtdIns(4,5)P2-immunoposi-
tive fine granules were colocalized with PICALM (Fig-
ure 3m, n) and pMEK (Figure 3o, p). Furthermore, the
signals for several tau kinases, such as GSK-3b and
pSyk, which is a newly identified tau kinase [26] that
is expressed in hippocampal pyramidal neurons of AD
patients and detected in GVD bodies [27], were found
to colocalize with PtdIns(4,5)P2-immunopositive fine
granules (Figure 3q–t).
PtdIns(4,5)P2-immunopositive small granules
are segregated from phosphorylated tau
proteins within NFTs in pyramidal neurons
Although single neurons showed immunoreactivity for
both PtdIns(4,5)P2 and AT8, distinct distribution pat-
terns were detected that showed that PtdIns(4,5)P2
and AT8 are mutually exclusive, as previously reported
[27] (Figure 4a–c). A representative fluorescence inten-
sity line scan profile is shown in Figure 4d. The peaks
for PtdIns(4,5)P2 and AT8 appeared alternately, and
the Pearson coefficient for the correlation between the
fluorescence intensities was 0.406, indicating a rela-
tively low correlation between the locations of PtdIns
(4,5)P2 and AT8.
Super-resolution microscopic images of PtdIns(4,5)
P2-immunopositive materials within GVD bodies and
NFTs are shown in Figure 4e–h. Some accumulations
of PtdIns(4,5)P2-immunopositive granules were
observed in the cytoplasm of a pyramidal cell in the
hippocampus of an AD patient, indicative of GVD bod-
ies. On the other hand, scattered PtdIns(4,5)P2-immu-
nopositive small granules were located adjacent to
accumulations of AT8-positive granules, indicative of
NFTs. As revealed by immunohistochemistry, inside a
GVD body, both the granules surrounded by a vesicle,
and the vesicle itself were positively stained for PtdIns
(4,5)P2; however, based on immunofluorescence stain-
ing, within a GVD body, immunoreactivity for PtdIns
(4,5)P2 seemed to be present only on granules within
a vesicle and not on the outer membrane.
GVD body-like small vesicles are located
adjacent to PHFs
An ultrastructural image of a pyramidal cell in the
subiculum of an AD patient is shown in Figure 5.
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Several vesicular structures with a diameter of
approximately 1 lm that contained central granules
surrounded by a halo-like clear zone and an outer
membrane, which structurally resembled GVD bod-
ies, were present in a gap between PHFs. Some of
these structures contained granules with high elec-
tron density, and others had intraluminal granule
formations. Such clusters of vesicles were sur-
rounded by PHFs.
Discussion
Previously, we showed that PtdIns(4,5)P2 is enriched in
both GVD bodies and NFTs. We have also demonstrated
that these structures are immunopositive for the raft mar-
ker flotillin-1, indicative of its association with lipid raft
domains. In this study, we analysed PtdIns(4,5)P2-
immunopositive material in detail, using super resolution
and electron microscopy and found that the PtdIns(4,5)
P2-immunopositivity that accumulates in pretangles cor-
responds to small vesicles with a mean diameter of
approximately 1 lm. Double immunofluorescence stain-
ing for PtdIns(4,5)P2 and AT8 and electron microscopic
images showed that the PtdIns(4,5)P2-immunopositive
vesicles were surrounded by PHFs in a‘islands in the sea’
pattern (Figure 6). Gray et al. [28] observed that PHFs
originate from the surface of membranous structures that
often contain dense granules. In addition to flotillin-1,
these PtdIns(4,5)P2-immunopositive raft-derived vesicles
contain several tau kinases, suggesting that the vesicles
have some role in the formation of PHFs. To our knowl-
edge, such raft-derived tau-associated vesicles (hereafter
referred to as RTVs) have not previously been described in
detail.
We and others have reported the accumulation of
flotillin-1-immunopositive vesicles in the pyramidal
neurons of AD patients [5]. Flotillin-1 is integrated into
lipid raft microdomains via palmitoylation and mediates
endocytosis upon receptor stimulation. Several lines of
evidence indicate that flotillin microdomains represent
assembly sites for active signalling platforms [29,30].
Recently, apart from tau, several molecules, including
several lipid raft-associated proteins such as annexin 2
[31], and tau kinases, such as GSK-3b [31], have been
reported to accumulate in the pyramidal neurons of
AD patients. PICALM is colocalized with phosphory-
lated tau not only in NFTs but also in GVD bodies [25].
The presence of PICALM is notable due to its ability
to bind with PtdIns(4,5)P2 [32], suggesting it is
associated with PtdIns(4,5)P2-immunopositive RTVs.
Although the vesicular-staining pattern of PICALM
resembles that of PtdIns(4,5)P2, PICALM has been
reported to be localized on PHFs and not on vesicular
structures. Pei and colleagues demonstrated the accu-
mulation of CDK5 in the neurons of individuals in the
early stages of AD [10]. We have previously shown
that CDK5-immunopositive granules are present in hip-
pocampal neurons and colocalize with AT8-immunopo-
sitive phosphorylated tau proteins. Syk, a newly
identified tau kinase [26] that acts downstream of the
TREM2 signalling cascade, is expressed in the hip-
pocampal pyramidal neurons of patients with Nasu–
Hakola disease and AD and is detected in GVD bodies
[27]. Although little is known about the role of Syk in
AD, it is noteworthy that TREM2 variants are a risk
factor for AD. In this study, we revealed that Syk
expressed in pyramidal neurons is localized to RTVs as
well as to GVD bodies. Accordingly, the increase in the
levels of multiple tau kinases in pyramidal neurons
seems to coincide with the accumulation of RTVs.
Recently, it was demonstrated that endosomal mem-
branes can serve as a recruitment platform for sig-
Figure 3. Double immunofluorescence staining for phosphatidylinositol-4,5-bisphosphate [PtdIns(4,5)P2] (green) and charged
multivesicular body protein 2B (CHMP2B) (red) (a), PtdIns(4,5)P2 (green) and AT8 (red) (c), PtdIns(4,5)P2 (green) and RD4 (red) (e),
and PtdIns(4,5)P2 (green) and RD3 (red) (g) in neuronal cells in an Alzheimer’s disease case. Thereafter, the same sections were
subjected to Gallyas-Braak staining (b, d, f, h). PtdIns(4,5)P2-immunopositive fine granules that were immunonegative for CHMP2B and
segregated from AT8 colocalized with RD4 but not with RD3 (arrows). Some of their regions were negative for Gallyas-Braak stain,
indicating that they were pretangles (arrowheads). Double immunofluorescence staining for PtdIns(4,5)P2 (green) and Tau-C3 (red) (i),
PtdIns(4,5)P2 (green) and AT8 (red) (j), PtdIns(4,5)P2 (green) and AT100 (red) (k), and PtdIns(4,5)P2 (green) and AT270 (red) (l).
PtdIns(4,5)P2-immunopositive small granules were colocalized with Tau-C3 but not with AT8, AT100 or AT270, as shown in the
spectrally unmixed images. Double immunofluorescence staining for PtdIns(4,5)P2 (green) and phosphatidylinositol-binding clathrin
assembly protein (PICALM) (red) (m, n), PtdIns(4,5)P2 (green) and pMEK (red) (o, p), PtdIns(4,5)P2 (green) and glycogen synthase
kinase (GSK)-3b (red) (q, r) and PtdIns(4,5)P2 (green) and phosphorylated spleen tyrosine kinase (pSyk) (red) (s, t). PtdIns(4,5)P2-
immunopositive small granules were colocalized with PICALM, pMEK and several tau kinases, such as GSK-3b and pSyk. Scale bars:
10 lm (a–l, n, p, r, t), 20 lm (m, o, q, s).
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Figure 4. Colocalization analysis of phosphatidylinositol-4,5-bisphosphate [PtdIns(4,5)P2] with AT8 in a neuronal cell in an Alzheimer’s
disease (AD) case. Double immunofluorescence staining for PtdIns(4,5)P2 (a) and AT8 (b) and the pseudocoloured image for PtdIns(4,5)
P2 (green) and AT8 (red) (c). The fluorescence intensity profile along the white dotted line is shown in (d). au, arbitrary unit. The
inverse correlation between PtdIns(4,5)P2 and AT8 indicates that these molecules segregated from each other. Super-resolution
microscopic image of PtdIns(4,5)P2- and AT8-immunopositive structures in a neuronal cell in an AD case, as revealed by double
immunofluorescence staining (e–h); PtdIns(4,5)P2 (e), AT8 (f), Hoechst (g) and the superimposed image (h). A number of PtdIns(4,5)P2-
immunopositive granules are sprinkled over the granular and filamentous materials that are immunopositive for AT8 (arrowheads).
Some PtdIns(4,5)P2-immunopositive granules formed aggregates and were accompanied by a halo-like clear zone (arrows), suggesting
that they were granulovacuolar degeneration bodies. Scale bars: 10 lm.
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nalling complexes that are regulated by scaffold pro-
teins. These endosomes are called ‘signaling endosomes’
and use flotillin-1 as a scaffold protein [33–35]. The
presence of flotillin-1 and an array of tau kinases on
RTVs suggests that RTVs act as signalling endosomes
on which the tau protein is phosphorylated. The reten-
tion of endosomes as RTVs and the sustained activation
of tau kinases may be attributable to the impaired lyso-
somal degradation of the endocytic compartment for
some unspecified reason [36]. Furthermore, because
recent work has shown that anionic lipid membranes
can themselves induce tau aggregation, the surfaces of
Figure 5. Electron microscopic images of phosphatidylinositol-4,5-bisphosphate-immunopositive vesicles in a neuronal cell in an
Alzheimer’s disease (AD) case. Panels b and d were produced by tracing the pictures in a and c. Several granulovacuolar degeneration
bodies (G) and smaller vesicles with a diameter of 1 lm (arrows) were present in the cytoplasm around the nucleus (N) of a neuronal
cell, and some of them contained granules with high electron density (arrowheads) that were distinct from lipofuscin (filled triangles)
and/or had intraluminal granule formations (empty triangles) adjacent to paired helical filaments (*). Other neuronal cells from the same
AD case also contained similar structures within the cytoplasm (e–h). Scale bars: 5 lm (a, b), 2 lm (e, g), 1 lm (c, d, f), 500 nm (h).
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RTVs, which contain negatively charged PtdIns(4,5)P2,
may be a site at which PHFs accumulate and grow into
NFTs [37,38]. This might explain why RTVs exist near
PHFs.
Granulovacuolar degeneration bodies manifest as
small inclusions that consist of 3- to 5-lm-diameter
spherical vacuoles-containing argentophilic and elec-
tron-dense granules [1]. The presence of electron-dense
granules is a shared feature of GVD bodies and RTVs.
Okamoto et al. [12] reported the accumulation of small
vesicles reminiscent of RTVs in close vicinity to GVD
bodies by electron microscopic examination. Because of
their morphological similarity, RTVs can be considered
miniature GVD bodies, and it is likely that GVD bodies
and RTVs have the same origin, as indicated by the
similarity of their molecular profiles. Taking size into
account, some vesicle fusion processes might lead to
the formation of GVD bodies. Other than fusion, vesi-
cles could cluster and pile up to create flame-shaped
RTVs by an unknown mechanism (Figure 7). In addi-
tion to the difference in their size, however, RTVs differ
from GVD bodies with respect to the presence of
CHMP2B. CHMP2B is a subunit of the ESCRT III com-
plex that mediates the formation of multivesicular bod-
ies (MVBs) and/or amphisomes and is reported to be a
marker of GVD bodies, but RTVs are negative for
CHMP2B. The immunoreactivity of GVD bodies for
CHMP2B suggests a failure of the MVBs to fuse with
lysosomes in the endocytic pathway during the forma-
tion of GVD bodies; this could also account for the
increased size of the vesicles. Therefore, the differences
in the stages of vesicle trafficking may be reflected in
the distinct properties of GVD bodies and RTVs
(Table 2). The mode of accumulation of RTVs that pre-
cedes the maturation of NFTs would define the final
Figure 6. Proposed model for the spatial relationships between
granulovacuolar degeneration (GVD) bodies, paired helical
filaments (PHFs) and raft-derived tau-associated vesicles (RTVs).
GVD bodies and RTVs are located adjacent to PHFs in an ‘islands
in the sea’ pattern.
Figure 7. Proposed model for the relationship between
granulovacuolar degeneration (GVD) bodies and raft-derived tau-
associated vesicles (RTVs). RTVs fuse with each other and form
GVD bodies. However, vesicles are clustered into RTVs, forming
the outline of Neurofibrillary tangles.























(+) positive, () negative
GVD, granulovacuolar degeneration; RTV, raft-derived tau-asso-
ciated vesicle; PtdIns(4,5)P2, phosphatidylinositol-4,5-bispho-
sphate; PICALM, phosphatidylinositol-binding clathrin assembly
protein; GSK, glycogen synthase kinase; CK-1d, casein kinase 1d;
CDK5, cyclin-dependent kinase 5; MEK, mitogen-activated protein
kinase kinase; CHMP2B, charged multivesicular body protein 2B.
© 2015 The Authors Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British
NAN 2016; 42: 639–653
650 T. Nishikawa et al.
shape of the NFTs, and RTVs themselves would be
another substructure of NFTs in addition to PHFs. The
number of neurons with GVD bodies increases with the
level of accumulation of phosphorylated tau [39], and
GVD stage is correlated with the NFT stage [13].
Because the number of GVD bodies is followed by that
of RTVs and because NFTs formation is preceded by
RTV formation, RTVs may quantitatively connect GVD
bodies and NFTs in various tauopathies.
In this study, we revealed that RTVs exist mainly in
pretangles and NFTs at a relatively early stage. Pei
et al. [28] reported that activated extracellular-signal-
regulated protein kinase 1/2- and MEK 1/2-immunopo-
sitive granules are present in neuronal cells with NFTs
and that these proteins are associated with the progres-
sion of neurofibrillary degeneration in AD. These gran-
ules resemble RTVs, in that they exist in early tangles
and decrease in number during the maturation of tan-
gles. Therefore, these proteins may be components of
RTVs and associated with the generation of PHFs
through tau phosphorylation.
Our study has several methodological limitations. We
revealed the existence of RTVs in pretangles and
showed their immunohistochemical profile but could
not prove that RTVs form NFTs. To verify this possibil-
ity, an experimental system using animal models and
cultured cell lines needs to be established.
In conclusion, we have demonstrated that clusters of
raft-derived vesicles containing tau kinase form a sub-
structure of pretangles distinct from PHFs. These vesi-
cles are related to GVD bodies and are likely involved
in the aggregation and modification of tau protein as
well as, accordingly, the formation of PHFs. Further
investigation of the mechanisms underlying RTV for-
mation will shed light on the pathological process
behind AD.
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